Skip to content

The effect of laughing gas on brain elctirc activity and mood

The effect of nitrous oxide on EEG and mood: a randomized double blinded study

Status
Not yet recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2018-001818-15-FI
Enrollment
40
Registered
2020-10-05
Start date
2020-11-10
Completion date
Unknown
Last updated
2020-11-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression The main aim of this study is to understand how N2O affects - during gas exposure and upon gas withdrawal - slow EEG oscillations in healthy adult volunteers. The aim is to understand the individual variation to the treatments, the dose-response effects of the treatments and the effect of intermittent dosing of the treatments on EEG.

Interventions

Trade Name: Nitrous oxide Product Name: Nitrous oxide Pharmaceutical Form: Inhalation vapour

Sponsors

Tampere University Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 18-40 years, BMI 18-27 Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 40 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: no medication/chronic illness, no previous history of psychiatric or substance abuse disorders,

Design outcomes

Primary

MeasureTime frame
Main Objective: The main aim of this study is to understand how N2O affects - during gas exposure and upon gas withdrawal - slow EEG oscillations in healthy adult volunteers. ;Secondary Objective: The impact of the treatments on cognitive functions and psychological state ;Primary end point(s): Slow wave oscillations (EEG) ;Timepoint(s) of evaluation of this end point: During administration and directly after administration

Secondary

MeasureTime frame
Secondary end point(s): Cantab, SCL90 ;Timepoint(s) of evaluation of this end point: Directly after administration

Countries

Finland

Contacts

Public ContactSimo Varila

Tampere University Hospital

+358505128189

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026